drugset
drugset / Trial / NCT01246089

Ranibizumab for Myopic Neovascularization

NCT01246089 ↗

Phase 4 Unknown 20 enrolled Instituto de Olhos de Goiania
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).

Timeline

Start
2009-07
Primary completion
2014-10
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody 0.5 mg Intravitreal

Indications

choroidal neovascularization